<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418093</url>
  </required_header>
  <id_info>
    <org_study_id>04-356</org_study_id>
    <nct_id>NCT00418093</nct_id>
  </id_info>
  <brief_title>Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma</brief_title>
  <official_title>A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to begin to collect information and try to learn whether or
      not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with
      recurrent mullerian carcinoma. We will also collect more information about the safety and
      side effects of this combination of drugs. Gemcitabine and oxaliplatin are chemotherapy drugs
      that kill cancer cells. Bevacizumab is a new anti-cancer drug that works to slow or stop cell
      growth in cancerous tumors by decreasing the blood supply to the tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study treatment is divided into periods called cycles. Each cycle is 28 days long.
           Participants will be given the study drugs intravenously on day 1 and day 15 of each
           cycle.

        -  Gemcitabine will be given first, over a period of 30 minutes. Then oxaliplatin over a
           period of 2 hours. Finally, bevacizumab will be given over a period of 30 to 90 minutes.
           Participants will continue study treatment as long as their tumor is not growing and
           they are not experiencing unacceptable side effects. If the tumor goes away completely,
           the participant will have 2 more cycle of study treatment.

        -  Blood will be drawn for routine testing every week during study treatment to check for
           side effects. Before day 1 and 15 of each cycle the following tests and procedures will
           be performed: a medical history; complete physical exam; vital signs; blood tests; and
           urine tests. Before day 1 of every other cycle, the following additional procedures will
           be performed: A CT scan, x-ray or ultrasound of your abdomen and pelvis; an x-ray of the
           chest (if required by the study doctor); blood tests; and urine samples.

        -  If the participant's tumor goes away, they will be asked to return to the clinic for
           follow-up visits every 3 months for 2 years, then every 6 months for 3 years. At each
           follow-up visit the following tests and procedures will be performed: medical history;
           complete physical examination; CT scan, x-ray or ultrasound of the abdomen and pelvis;
           x-ray of the chest; and other tests if the doctor feels they are needed.

        -  There is an optional sub-study that six subjects will be asked to take a part in that
           will give the study doctors important information about the way the body uses and breaks
           down the study drugs. This sub-study will involve special surgical procedures and scans
           that will be done during cycle 1 of the study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    THe study was terminated early due to a lack of accural
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Response Rate</measure>
    <time_frame>Outcome was assessed every 2 cycles (every 8 weeks) for the duration on study, an average of 4.5 cycles (18 weeks)</time_frame>
    <description>Precentage of women who responded to the treatment regimen Response was determined by RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Assessed every 2 cycles (every 8 weeks) of chemotherapy until progression of disease is documented with a median duration of follow up of 24 months</time_frame>
    <description>Time participant remains free of progression of her disease. Evaluated by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed every 3 months until death from disease, other causes, or loss to follow up at a median follow up of 24 months</time_frame>
    <description>Duration of time participants are alive after enrolling on the study. Assessed by clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Nature and Degree of Toxicities Following Treatment With Oxaliplatin, Gemcitabine, and Bevacizumab in This Patient Population.</measure>
    <time_frame>Toxicities were assessed every cycle and for up to 30 days after being removed from the trial</time_frame>
    <description>The nature and toxicities of treatment were graded per the National Cancer Institute Common Terminology Criteria of Adverse Events version 3.0 Patients with grade 2 or higher toxicity were reported</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received oxaliplatin, gemcitabine, and bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic or
             cytologic confirmation of the original primary tumor is required.

          -  Must have measurable disease which is defined as at least one lesion that can be
             accurately measured in at least one dimension. Each lesion must be &gt;20mm when measured
             by conventional techniques.

          -  Must have at least one &quot;target lesion&quot; to be used to assess response.

          -  Platinum-sensitive tumors, defined as a platinum free interval of at least 6 months,
             and may have had up to two prior treatment regimens.

          -  Eastern Cooperative Oncology Group score of 0 or 1

          -  Life expectancy of 12 weeks or longer

          -  18 years of age or older

          -  Adequate bone marrow, renal, neurologic and liver function

          -  Normal blood coagulation parameters

        Exclusion Criteria:

          -  Chemotherapy within last 3 weeks

          -  Current, recent (within 4 weeks), or planned participation in an experimental drug
             study other than a Genentech-sponsored bevacizumab cancer study.

          -  Known bleeding disorder or coagulopathy, or history of stroke.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study entry or the anticipation of need for major surgical procedure during
             the course of the study.

          -  Minor surgical procedures within 14 days of study entry.

          -  Significant cardiovascular disease, New York Heart Association Grade II or greater
             congestive heart failure, serious cardiac arrhythmia requiring medication, a history
             of deep vein thrombosis, or Grade II or greater, clinically significant peripheral
             vascular disease within 1 year of study entry.

          -  Urine protein:creatinine ration greater than or equal to 1.0

          -  History or clinical evidence of central nervous system disease

          -  Patients with other invasive malignancies, with the exception of non-melanoma skin
             cancer, who have evidence of disease within last three years.

          -  More than 2 prior lines of chemotherapy

          -  Previous treatment with a VEGF targeted inhibitor or antibody

          -  Serious non-healing wound, ulcer or bone fracture

          -  Prior radiation therapy to more than one-third of hematopoietic sites.

          -  History of abdominal fistulas, gastrointestinal perforation, intra-abdominal abscess,
             or partial bowel obstruction within 6 months

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Horowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>April 27, 2012</results_first_submitted>
  <results_first_submitted_qc>June 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2014</results_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Neil S. Horowitz, MD</investigator_full_name>
    <investigator_title>Gynecologic Oncologist</investigator_title>
  </responsible_party>
  <keyword>mullerian carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy Group</title>
          <description>Oxaliplatin plus Gemcitabine plus Bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Partial Response Rate</title>
        <description>Precentage of women who responded to the treatment regimen Response was determined by RECIST criteria</description>
        <time_frame>Outcome was assessed every 2 cycles (every 8 weeks) for the duration on study, an average of 4.5 cycles (18 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy Group</title>
            <description>Oxaliplatin, Gemcitabine, Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response Rate</title>
          <description>Precentage of women who responded to the treatment regimen Response was determined by RECIST criteria</description>
          <units>percentage of patients on study</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Proportion</param_type>
            <param_value>0.684</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>Point estimate of PR and its exact 95% CI based on Binomial Model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Single Proportion</param_type>
            <param_value>0.684</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.434</ci_lower_limit>
            <ci_upper_limit>0.874</ci_upper_limit>
            <estimate_desc>Estimation of a single proportion (partial response rate) with exact 95% Binomial confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time participant remains free of progression of her disease. Evaluated by RECIST criteria</description>
        <time_frame>Assessed every 2 cycles (every 8 weeks) of chemotherapy until progression of disease is documented with a median duration of follow up of 24 months</time_frame>
        <population>19</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy Group</title>
            <description>Oxaliplatin, Gemcitabine, Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time participant remains free of progression of her disease. Evaluated by RECIST criteria</description>
          <population>19</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" lower_limit="12" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Duration of time participants are alive after enrolling on the study. Assessed by clinical records</description>
        <time_frame>Assessed every 3 months until death from disease, other causes, or loss to follow up at a median follow up of 24 months</time_frame>
        <population>All patients enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy Group</title>
            <description>Oxaliplatin, Gemcitabine, Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Duration of time participants are alive after enrolling on the study. Assessed by clinical records</description>
          <population>All patients enrolled</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.3" lower_limit="90.4" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Nature and Degree of Toxicities Following Treatment With Oxaliplatin, Gemcitabine, and Bevacizumab in This Patient Population.</title>
        <description>The nature and toxicities of treatment were graded per the National Cancer Institute Common Terminology Criteria of Adverse Events version 3.0 Patients with grade 2 or higher toxicity were reported</description>
        <time_frame>Toxicities were assessed every cycle and for up to 30 days after being removed from the trial</time_frame>
        <population>All patients enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy Group</title>
            <description>Oxaliplatin, Gemcitabine, Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Nature and Degree of Toxicities Following Treatment With Oxaliplatin, Gemcitabine, and Bevacizumab in This Patient Population.</title>
          <description>The nature and toxicities of treatment were graded per the National Cancer Institute Common Terminology Criteria of Adverse Events version 3.0 Patients with grade 2 or higher toxicity were reported</description>
          <population>All patients enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE v3.0">Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction to Oxaliplatin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was closed after enrolling 19 of the 53 projected patient accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Neil Horowitz, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-732-8843</phone>
      <email>nhorowitz@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

